BACKGROUND: Primary squamous cell carcinomas (SCC) of the colon are extremely rare and occur predominantly in the fifth decade of life, with a slight prevalence in men. The most common anatomical sites are the rectum and the proximal colon. Clinical signs and common dia-gnostic methods cannot clearly distinguish SCC from adenocarcinoma. METHODS: In this case report, we present a case of a 68-year-old patient with SCC of the cecum and colon ascendens, who was treated with resection and systemic gemcitabine- and cisplatin-based chemotherapy. RESULTS: A 68-year-old patient underwent right-sided hemicolectomy for cecal and colon ascendens tumor, histologically poorly differentiated epidermoid carcinoma, grade 3 with an initial stage of pT4aN1aM0. Due to local recurrence at the resection site with suspected infiltration of straight and oblique abdominal muscles, he was treated with systemic gemcitabine and cisplatin based chemotherapy with partial remission. Subsequently, the postchemotherapeutic residual tumor was radically resected, achieving complete remission of the disease, which persists for 10 months after the surgery. CONCLUSION: The case emphasizes the need for a multidisciplinary treatment approach of this rare disease. Early surgery plays a key role. Although the standard chemotherapy regimen is not well defined, the use of a combination of cisplatin and gemcitabine resulted in partial remission in our patient, which in turn allowed a radical resection of the relapse and subsequently achieved complete remission of the disease.

• Klíčová slova
• colorectal, squamous cell carcinoma, systemic treatment,
• MeSH
• cisplatina aplikace a dávkování   MeSH
• deoxycytidin aplikace a dávkování   analogy a deriváty   MeSH
• gemcitabin MeSH
• lidé MeSH
• nádory tračníku farmakoterapie   patologie   chirurgie   MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• senioři MeSH
• spinocelulární karcinom farmakoterapie   patologie   chirurgie   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• cisplatina MeSH
• deoxycytidin MeSH
• gemcitabin MeSH

BACKGROUND: Metastatic pancreatic carcinoma is an aggressive disease with adverse prognosis. Despite slight advances in chemotherapy, complete remission of the disease is extremely rare. CASE: In this article we present a case of a patient with initially metastatic pancreatic adenocarcinoma, associated with double heterozygous germline mutation in BRCA2 and CHEK2 genes, with the description of clinical, radiological and histomorphological characteristics of the disease as well as the dia-gnostic and therapeutic procedure. RESULTS: The patient with initially metastatic pancreatic adenocarcinoma with multiple liver involvement achieved complete remission following first-line FOLFIRINOX chemotherapy. The treatment lasted for 12 months but due to increased neurotoxicity since the 9th cycle, oxaliplatin was excluded from the regimen. Given the family history of several malignancies (prostate cancer, seminoma), genetic testing was performed, which confirmed heterozygous germline mutations in BRCA2 and CHEK2 genes. Since the treatment has been completed, the patient remains in complete remission at 30 months. CONCLUSION: Given the low incidence of complete remissions in patients with metastatic pancreatic cancer, the further therapeutic approach is not clearly established, an individual treatment is important. Universal genetic testing is recommended in patients with pancreatic cancer as it may affect the treatment strategy.

• Klíčová slova
• BRCA2, CHEK2, DNA repair, chemotherapy, germline mutation, pancreatic cancer, remission,
• MeSH
• adenokarcinom * farmakoterapie   genetika   MeSH
• checkpoint kinasa 2 * genetika   MeSH
• fluoruracil terapeutické užití   MeSH
• genetická predispozice k nemoci MeSH
• geny BRCA2 MeSH
• irinotekan terapeutické užití   MeSH
• leukovorin terapeutické užití   MeSH
• lidé MeSH
• nádory slinivky břišní * farmakoterapie   genetika   MeSH
• oxaliplatin terapeutické užití   MeSH
• protein BRCA2 * genetika   MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• rodokmen MeSH
• zárodečné mutace MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• checkpoint kinasa 2 * MeSH
• CHEK2 protein, human MeSH Prohlížeč
• fluoruracil MeSH
• folfirinox MeSH Prohlížeč
• irinotekan MeSH
• leukovorin MeSH
• oxaliplatin MeSH
• protein BRCA2 * MeSH